

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

01 February 2024 (01.02.2024)



(10) International Publication Number

WO 2024/026486 A3

(51) International Patent Classification:

A61K 31/438 (2006.01) A61K 31/496 (2006.01)

A61K 31/503 (2006.01) A61K 31/33 (2006.01)

A61K 31/166 (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(21) International Application Number:

PCT/US2023/071258

(22) International Filing Date:

28 July 2023 (28.07.2023)

(88) Date of publication of the international search report:

04 April 2024 (04.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/393,066 28 July 2022 (28.07.2022) US

(71) Applicant: CEDILLA THERAPEUTICS, INC.

[US/US]; 245 First Street, 3rd Floor, Cambridge, Massachusetts 02142 (US).

(72) Inventors: KIRMAN, Louise Clare; 35 Elmwood Road,

Swampscott, Massachusetts 01907 (US). SCHWARTZ,

Carl Eric; 309 Atlantic Ave., Marblehead, Massachusetts

01945 (US). BLAISDELL, Thomas P.; 212 Westminster

Ave., Watertown, Massachusetts 02472 (US).

(74) Agent: REID, Andrea L.C. et al.; c/o Dechert LLP, One

International Place, 40th Floor, 100 Oliver Street, Boston,

Massachusetts 02110-2605 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,

KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,

ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,

GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: CDK2 INHIBITORS AND METHODS OF USING THE SAME

(57) Abstract: The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.



WO 2024/026486 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 23/71258

A. CLASSIFICATION OF SUBJECT MATTER

IPC - INV. A61K 31/438, A61K 31/503, A61K 31/166, A61K 31/496 (2023.01)
ADD. A61K 31/33 (2023.01)

CPC - INV. A61K 31/438, A61K 31/503, A61K 31/166, A61K 31/496

ADD. A61K 31/33

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2021/021996 A1 (Aptinyx Inc. et al.), 04 February 2021 (04.02.2021), entire document, especially para[0069], [0097], [00107]	1, 3
A	WO 2020/086739 A1 (Araxes Pharma LLC), 30 April 2020 (30.04.2020), entire document, especially page 8, ln 24-25; page 28, ln 19-25; page 29, ln 1-31; page 30, ln 6-7	1, 3
A	"Pubchem CID 132447109", Create date: 08 March 2018 (08.03.2018), entire document, especially page 2, compound listed	1, 3
A	"Pubchem CID 137892078", Create date: 26 April 2019 (26.04.2019), entire document, especially page 2, compound listed	1, 3
A	US 2020/0407374 A1 (The Trustees of the University of Pennsylvania), 31 December 2020 (31.12.2020), entire document, especially para[0008], [0055], [0186]	1, 3
X, P	WO 2022/165513 A1 (Cedilla Therapeutics, Inc.), 04 August 2022 (04.08.2022), entire document, especially para[0004]-[0007], [0047]; Table 1	1, 3

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"D" document cited by the applicant in the international application

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

02 November 2023 (02.11.2023)

Date of mailing of the international search report

JAN 22 2024

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents

P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Kari Rodriguez

Telephone No. PCT Helpdesk: 571-272-4300

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 23/71258

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

- 1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

- 2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

- 3. Claims Nos.: 5-44, 46-57
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
---see supplemental box---

- 1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
- 2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
- 3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

- 4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1, 3

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 23/71258

Box III: lack of unity

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I+: Claims 1-4 and 45 are directed to a compound of Formula IA as seen in instant claim 1. Claim 1 will be searched to the extent that it encompasses the first species of claim 1, represented by a compound of Formula IA wherein RA is the first structure listed; RB is H; L1 is a covalent bond; R1 is H; R2 is H; R3 is H; R is H; L2 is a saturated, straight, bivalent C1 hydrocarbon chain (i.e., -CH2-); R6 is C1 aliphatic group (i.e., methyl); L3 is a saturated, straight, bivalent C1 hydrocarbon chain (i.e., -CH2-); R8 is a cyclic group selected from 3-membered saturated monocyclic carbocyclic ring (i.e., cyclopropyl). It is believed that claims 1 and 3 read on this first named invention, and thus these claims will be searched without fee. This first named invention has been selected based on the guidance set forth in section 10.54 of the PCT International Search and Preliminary Examination Guidelines. Applicant is invited to elect additional compounds of claim 1, wherein each additional compound elected will require one additional invention fee. Applicants must specify the claims that encompass any additionally elected compound. Applicants must further indicate, if applicable, the claims which encompass the first named invention, if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the '+' group(s) will result in only the first claimed invention to be searched. Additionally, an exemplary election wherein different actual variables are selected is suggested. An exemplary election would be a compound of Formula IA wherein RA is the first structure listed; RB is H; L1 is a covalent bond; R1 is C1 aliphatic group (i.e., methyl); R2 is H; R3 is H; R is H; L2 is a saturated, straight, bivalent C1 hydrocarbon chain (i.e., -CH2-); R6 is C1 aliphatic group (i.e., methyl); L3 is a saturated, straight, bivalent C1 hydrocarbon chain (i.e., -CH2-); R8 is a cyclic group selected from 3-membered saturated monocyclic carbocyclic ring (i.e., cyclopropyl) (i.e., claims 1, 3).

The group of inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Special Technical Features:

Each invention in Group I+ includes the technical feature of a unique compound of Formula IA, which is not required by any other invention of Group I+.

Common Technical Features:

The inventions of Groups I+ share the technical feature of a compound of Formula IA.

These shared technical features, however, do not provide a contribution over the prior art as being anticipated by a document entitled "Pubchem CID 137892078" (hereinafter 'Pubchem-078'). Pubchem-078 teaches a compound of Formula IA as seen in instant claim 1 or a pharmaceutically acceptable salt thereof, wherein: RA is the first structure listed in instant claim 1 wherein L1 is a covalent bond, R1 is a C3 aliphatic group (i.e., -CH(CH3)2), R2 is H, R3 is H, and R is H; RB is H; L2 is a saturated, straight, bivalent C3 hydrocarbon chain wherein 1 methylene unit of L2 is replaced by -C(O)NR wherein R is H; R6 is phenyl; L3 is a saturated, straight, bivalent C1 hydrocarbon chain; R8 is phenyl (see page 2, compound listed).

As said compound was known in the art at the time of the invention, these cannot be considered special technical features that would otherwise unify the inventions of Groups IA. The inventions of Group IA thus lack unity under PCT Rule 13.

Item 4 (cont.):

Claims 5-44 and 46-57 are unsearchable because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).